Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
Fernando Bril, Srilaxmi Kalavalapalli, Virginia Clark et al. · Clinical Gastroenterology and Hepatology · 2017
Cited by 199 works. doi:10.1016/j.cgh.2017.12.001
Authors
- Fernando Bril
- Srilaxmi Kalavalapalli
- Virginia Clark
- Romina Lomonaco
- Consuelo Soldevila‐Pico
- I‐Chia Liu
- Beverly Orsak
- Fermin O. Tio
- Kenneth J. Cusi
References
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
- Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance